Notably, according to KEYNOTE-024 results, pembrolizumab monotherapy is the standard first-line treatment for metastatic NSCLC with a PD-L1 Tumor Proportion Score (TPS) ≥ 50% [8]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.